BioCryst 2025: ORLADEYO breaks $600M, first full-year profitability and a bigger HAE franchise after Astria

1. Snapshot, market context and risk summary

From a RunUP Biotech perspective, BCRX is no longer a binary “one-catalyst bet” but a rare case where a once-speculative biotech has managed to build a scaled commercial asset, reach operating profitability and still maintain a pipeline that can move the needle. That said, equity risk has simply shifted from short-term survival to long-term competitive positioning in hereditary angioedema and to the binary transition from Phase 1 to registrational development in Netherton syndrome.

2. ORLADEYO franchise: from adult market to pediatric leadership

ORLADEYO remains the engine of BioCryst. In 2025 the drug delivered $601.8M in net revenue, up 38% year-on-year, with growth even stronger once the European divestiture is stripped out. That performance is what allowed BioCryst to post record operating profit and to finance both the Astria acquisition and continued pipeline work without falling back into a cash-burn spiral.

The most structurally important move in 2025 was not just “more revenue”, but the pediatric expansion. In December 2025, the FDA approved an oral pellet formulation of ORLADEYO for children aged 2 to <12 years with hereditary angioedema, turning ORLADEYO into the first and only targeted oral prophylactic option available from age 2 upwards in the U.S. market. The same formulation is being pursued in Europe and Japan through regulatory filings already initiated.

Strategically, this matters for three reasons. First, it anchors ORLADEYO earlier in the treatment journey: families that stabilise a child’s HAE with once-daily oral prophylaxis have a strong incentive to avoid switching away unless forced by efficacy or tolerability issues. Second, the pediatric launch supports the long-term narrative that ORLADEYO is not just a niche adult option but a backbone therapy across the HAE age spectrum. Third, it gives BioCryst a direct seat at the table in discussions around treatment burden, quality of life and long-term disease management for caregivers – areas where oral prophylaxis is structurally advantaged versus injectables and infusions.

The flip side is that pediatric HAE is a small population and payers can be very strict: safety, dosing convenience and attack-rate data will be scrutinised, and the competitive response from other HAE players (including those developing subcutaneous or long-acting injectables) should not be underestimated. ORLADEYO is now competing not only for adult share, but also for the “first seat at the table” in pediatric care pathways.

3. Astria acquisition and the “dual-platform” HAE strategy

In January 2026, BioCryst closed the acquisition of Astria Therapeutics, a roughly $700M cash-and-stock transaction originally announced in October 2025. The deal brings in navenibart, a long-acting injectable plasma kallikrein inhibitor in Phase 3 (ALPHA-ORBIT), with dosing regimens being studied every three months (Q3M) and every six months (Q6M). The Phase 3 program is designed to support regulatory filing by the end of 2027, with patients able to roll over from ALPHA-ORBIT into the ORBIT-EXPANSE long-term extension.

Fresh interim data from the ALPHA-SOLAR open-label trial shows sustained suppression of HAE attacks with both Q3M and Q6M dosing: mean reductions of about 90–92% and median reductions of about 97% from baseline in both arms, with safety profiles consistent with earlier studies. These are exactly the kind of numbers an injectable needs to justify its place in an increasingly crowded prophylaxis market.

For BioCryst, the strategic rationale is clear: ORLADEYO is the daily oral backbone, while navenibart targets patients who either prefer long-interval injections or require “maximal” prophylactic control. If the Phase 3 program reads out positively and regulators agree with the design, BioCryst could end up offering both the lowest-burden oral option and one of the lowest-frequency injectable options in HAE, creating internal flexibility to retain patients even when they cycle between treatment modalities over time.

The integration risk is real: BioCryst needs to manage clinical, regulatory and commercial execution for two HAE platforms while preserving momentum in ORLADEYO. But in terms of portfolio construction, the deal converts a single-product story into a more credible medium-term growth platform. Equity markets will likely judge BioCryst on how well management executes against the 2027 filing and on whether navenibart can avoid being “just another” late-comer in a competitive field.

4. BCX17725 and the Netherton syndrome opportunity

Away from HAE, BioCryst is quietly building a second pillar in rare dermatology through BCX17725, a KLK5 inhibitor designed as a disease-modifying treatment for Netherton syndrome, a severe inherited skin disorder with high unmet need. The company began enrolling a Phase 1 study in 2024, and by early 2026 the trial is dosing patients with the plan to report data in up to 12 Netherton patients by the end of 2026.

The Phase 1 design is multi-part, starting with healthy volunteers and progressing to patients with Netherton syndrome to assess safety, pharmacokinetics and early signs of activity. The scientific rationale – targeting KLK5 to correct the protease imbalance underlying Netherton – is well aligned with the pathophysiology of the disease, and the program fits BioCryst’s broader ambition of developing small and large molecule therapeutics for rare conditions.

From an equity perspective, BCX17725 is still in the high-risk, early-stage bucket: binary tolerability and signal-of-activity questions remain ahead of any registrational strategy. However, if early data are supportive, Netherton offers a space where even a relatively small, focused commercial build could be meaningful in terms of value creation, especially if the program is ultimately partnered or co-developed rather than brought to market entirely on BioCryst’s balance sheet.

5. Financials: 2025 results and 2026 guidance

On the numbers, 2025 marks a turning point for BioCryst. Total revenue reached $874.8M, almost doubling from $450.7M in 2024, driven by ORLADEYO growth and the $243.3M license revenue from the sale of the European ORLADEYO business to Neopharmed Gentili. Even on a non-GAAP basis, which removes the one-off impact of the European sale and certain adjustments, revenue grew 45% year-on-year to $592.9M.

Operating profitability is equally important: BioCryst posted a $341.0M GAAP operating profit in 2025, compared with a small operating loss the year before. On a non-GAAP basis, operating profit was $214.2M, up nearly 200% year-on-year. This is not just a cosmetic milestone: it shows that the commercial infrastructure built around ORLADEYO can now support the company while it absorbs integration costs and pipeline investment.

On the cost side, 2025 R&D (excluding stock-based compensation) came in at $136.6M, slightly down year-on-year, reflecting the closure of the Factor D program and lower personnel costs, offset by higher spending on BCX17725, avoralstat and early-stage pipeline work. Sales & marketing expenses rose to $177.1M on a GAAP basis as BioCryst invested behind ORLADEYO growth and the pediatric launch, while G&A increased to $116.0M as the company scaled its corporate functions.

Management maintained its guidance for 2026: global ORLADEYO net revenue between $625M and $645M, and total revenue (including RAPIVAB) between $635M and $660M, with non-GAAP operating expenses (excluding stock-based compensation and transaction costs) expected in the $450–470M range. Importantly, the company also paid off its Pharmakon term loan in 2025, reducing interest expense and simplifying the capital structure at the cost of a one-time extinguishment charge.

In practical terms, BioCryst starts 2026 with $337.5M in cash, cash equivalents, restricted cash and investments, and modest net cash utilisation once the European sale and loan payoff are stripped out. That gives the company breathing room to navigate integration, trial execution and potential volatility in ORLADEYO uptake without immediately returning to the equity markets – although the usual biotech caveat applies: no assumptions can be made about future financing decisions.

6. Valuation lens, risks and what to watch next

6.1 Street view and embedded expectations

At a share price around $7.5 (late February 2026), BCRX trades at a level where the market is effectively discounting robust ORLADEYO growth but remains sceptical about the sustainability of that growth and the ability of navenibart and BCX17725 to create incremental value. With a Street target range broadly in the $14–33 band and an average around $22, the gap between current price and analyst expectations reflects both the perceived upside and the execution risk in bringing the full HAE and dermatology platform to fruition.

6.2 Key risks

The main risks to the story can be grouped into four buckets:

Competitive pressure in HAE. ORLADEYO’s growth has been impressive so far, but HAE prophylaxis is a dynamic space with multiple oral and injectable competitors, some targeting similar convenience and efficacy claims. If competitors out-execute BioCryst in adult or pediatric segments, or if new entrants shift the standard-of-care again, revenue trajectories could deviate materially from current guidance.

Clinical and regulatory risk for navenibart. While interim ALPHA-SOLAR data are encouraging, Phase 3 is where benefit-risk and comparability to existing options will be judged. Any safety, immunogenicity or efficacy surprises could delay or damage the launch profile, particularly given the ambitious low-frequency dosing claim.

Early-stage risk for BCX17725. As a Phase 1 program, BCX17725 still carries high binary risk. Negative or inconclusive data in Netherton syndrome would not threaten BioCryst’s existence but would remove a meaningful optionality layer from the medium-term thesis.

Capital allocation and integration. The combination of the European divestiture, the Astria acquisition and pipeline spending requires disciplined capital allocation. Missteps in integration, over-expansion of commercial infrastructure or unexpected cost overruns could erode the benefits of 2025’s profitability milestone.

6.3 What to watch over the next 12–24 months

Over the next year or two, the BCRX story will likely be driven by a handful of concrete checkpoints: the pace of pediatric ORLADEYO uptake, the quality and reception of navenibart data at scientific meetings and in the Phase 3 read-out, and the first clinical signals from BCX17725 in Netherton syndrome. At the same time, investors will look for evidence that management can maintain a healthy cash position while executing on all these fronts – effectively proving that BioCryst is now running a platform, not living between one funding event and the next.

7. Previous Merlintrader coverage on BCRX

For readers who want to revisit how this story has evolved over time, here are two earlier Merlintrader deep dives on BioCryst and ORLADEYO that provide useful context on the pre-2025 phase of the investment case:

Together with the current update, these pieces form a continuous logbook: from the “can this company survive?” phase, to “can ORLADEYO scale?”, to today’s question: “can BioCryst turn a single franchise into a broader, durable rare-disease platform?”.